

Fernando Alarid-Escudero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/36483/publications.pdf>

Version: 2024-02-01

55
papers

1,083
citations

394421

19
h-index

454955

30
g-index

64
all docs

64
docs citations

64
times ranked

1549
citing authors

#	ARTICLE	IF	CITATIONS
1	An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. <i>Medical Decision Making</i> , 2023, 43, 3-20.	2.4	8
2	CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis. <i>Value in Health</i> , 2022, 25, 409-418.	0.3	3
3	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e838-e845.	5.8	16
4	Characterization and Valuation of the Uncertainty of Calibrated Parameters in Microsimulation Decision Models. <i>Frontiers in Physiology</i> , 2022, 13, .	2.8	1
5	Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison. <i>Medical Decision Making</i> , 2022, 42, 956-968.	2.4	4
6	The Household Secondary Attack Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Rapid Review. <i>Clinical Infectious Diseases</i> , 2021, 73, S138-S145.	5.8	82
7	Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. <i>Journal of the National Cancer Institute</i> , 2021, 113, 154-161.	6.3	46
8	Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101735.	2.4	18
9	BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling. <i>Frontiers in Physiology</i> , 2021, 12, 662314.	2.8	8
10	Covid-19 Vaccine Acceptance in California State Prisons. <i>New England Journal of Medicine</i> , 2021, 385, 374-376.	27.0	37
11	Prioritizing Research Informing Antibiotic Prophylaxis Guidelines for Knee Arthroplasty Patients. <i>JDR Clinical and Translational Research</i> , 2021, , 238008442110202.	1.9	0
12	COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors. <i>Journal of General Internal Medicine</i> , 2021, 36, 3096-3102.	2.6	37
13	Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies. <i>Lancet Public Health</i> , The, 2021, 6, e760-e770.	10.0	35
14	Age-specific rates of onset of cannabis use in Mexico. <i>Addictive Behaviors</i> , 2021, 122, 107038.	3.0	4
15	Dependence of COVID-19 Policies on End-of-Year Holiday Contacts in Mexico City Metropolitan Area: A Modeling Study. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110492.	0.9	2
16	Retention in Care, Mortality, Loss-to-Follow-Up, and Viral Suppression among Antiretroviral Treatment-Naïve and Experienced Persons Participating in a Nationally Representative HIV Pre-Treatment Drug Resistance Survey in Mexico. <i>Pathogens</i> , 2021, 10, 1569.	2.8	1
17	The Cost-Effectiveness of Non-Drug Interventions That Reduce Nursing Home Admissions for People With Dementia. <i>Innovation in Aging</i> , 2021, 5, 227-227.	0.1	0
18	Midwife-led care and obstetrician-led care for low-risk pregnancies: A cost comparison. <i>Birth</i> , 2020, 47, 57-66.	2.2	19

#	ARTICLE	IF	CITATIONS
19	Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 955-963.	6.3	37
20	Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio. <i>Pharmacoeconomics</i> , 2020, 38, 285-296.	3.3	4
21	Cost-effectiveness analysis of a multidisciplinary health-care model for patients with type-2 diabetes implemented in the public sector in Mexico: A quasi-experimental, retrospective evaluation. <i>Diabetes Research and Clinical Practice</i> , 2020, 167, 108336.	2.8	8
22	Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers. <i>MDM Policy and Practice</i> , 2020, 5, 238146832095240.	0.9	2
23	Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2710-2718.	2.5	14
24	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. <i>Value in Health</i> , 2020, 23, 734-742.	0.3	51
25	A Multidimensional Array Representation of State-Transition Model Dynamics. <i>Medical Decision Making</i> , 2020, 40, 242-248.	2.4	6
26	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. <i>Medical Decision Making</i> , 2020, 40, 314-326.	2.4	28
27	Validation of Microsimulation Models Used for Population Health Policy. , 2020, , 227-240.		3
28	MP73-07â€fINTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER CANCER: A COST ANALYSIS. <i>Journal of Urology</i> , 2020, 203, .	0.4	1
29	A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. <i>Value in Health</i> , 2019, 22, 1102-1110.	0.3	12
30	A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 649-655.	5.4	45
31	92 â€“ Comparing the Cost-Effectiveness of New Colorectal Cancer Screening Tests. <i>Gastroenterology</i> , 2019, 156, S-21.	1.3	1
32	A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling. <i>Pharmacoeconomics</i> , 2019, 37, 1329-1339.	3.3	28
33	Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies. <i>JAMA Internal Medicine</i> , 2019, 179, 867.	5.1	28
34	â€œTime Traveling Is Just Too Dangerousâ€but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. <i>Value in Health</i> , 2019, 22, 611-618.	0.3	22
35	The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. <i>Pharmacoeconomics</i> , 2019, 37, 871-877.	3.3	6
36	Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. <i>European Urology</i> , 2019, 75, 910-917.	1.9	34

#	ARTICLE	IF	CITATIONS
37	Force of infection of <i>Helicobacter pylori</i> in Mexico: evidence from a national survey using a hierarchical Bayesian model. <i>Epidemiology and Infection</i> , 2018, 146, 961-969.	2.1	10
38	Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. <i>Medical Decision Making</i> , 2018, 38, 400-422.	2.4	85
39	A Gaussian Approximation Approach for Value of Information Analysis. <i>Medical Decision Making</i> , 2018, 38, 174-188.	2.4	36
40	Nonidentifiability in Model Calibration and Implications for Medical Decision Making. <i>Medical Decision Making</i> , 2018, 38, 810-821.	2.4	19
41	Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. <i>Journal of Urology</i> , 2018, 200, 1215-1220.	0.4	36
42	Revisiting assumptions about age-based mixing representations in mathematical models of sexually transmitted infections. <i>Vaccine</i> , 2018, 36, 5572-5579.	3.8	2
43	MP17-11 ACTIVE SURVEILLANCE FOLLOW-UP STRATEGIES: A COST-EFFECTIVENESS ANALYSIS. <i>Journal of Urology</i> , 2018, 199, .	0.4	0
44	Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?. <i>Breast Journal</i> , 2017, 23, 401-409.	1.0	9
45	An Overview of R in Health Decision Sciences. <i>Medical Decision Making</i> , 2017, 37, 735-746.	2.4	73
46	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 1073-1085.	3.3	9
47	A Kinked Health Insurance Market: Employer-Sponsored Insurance under the Cadillac Tax. <i>American Journal of Health Economics</i> , 2017, 3, 455-476.	3.0	2
48	Force Of Infection Of <i>Helicobacter Pylori</i> In Mexico: Evidence From A National Survey. <i>Value in Health</i> , 2017, 20, A856.	0.3	0
49	Opportunity Cost Of Non-Rigorous Or Non-Transferable Research: Implications For Cost-Effectiveness Analysis. <i>Value in Health</i> , 2017, 20, A863.	0.3	0
50	Modeling the Cost-Effectiveness of Doula Care Associated with Reductions in Preterm Birth and Cesarean Delivery. <i>Birth</i> , 2016, 43, 20-27.	2.2	111
51	Calibration of Piecewise Markov Models Using a Change-Point Analysis Through an Iterative Convex Optimization Algorithm. <i>Value in Health</i> , 2015, 18, A814.	0.3	0
52	Registro de señales de EEG para aplicaciones de Interfaz Cerebro Computadora (ICC) basado en Potenciales Evocados Visuales de Estado Estacionario (PEVEE). <i>IFMBE Proceedings</i> , 2007, , 87-90.	0.3	1
53	Towards a Public Health Approach to Homicides in Mexico. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
54	Análisis de costo-beneficio: prevención del VIH/sida en migrantes en Centroamérica. <i>Salud Publica De Mexico</i> , 0, 55, 23.	0.4	4

#	ARTICLE	IF	CITATIONS
55	How Do COVID-19 Policy Options Depend on End-of-Year Holiday Contacts in Mexico City Metropolitan Area? A Modeling Study. SSRN Electronic Journal, 0, , .	0.4	0